A practical update on the use of bortezomib in the management of multiple myeloma

Oncologist

Volumn 11, Issue 1, 2006, Pages 51-61

  Miguel, Jesús San ^a   Bladé, Joan ^b   Boccadoro, Mario ^c   Cavenagh, Jamie ^d   Glasmacher, Axel ^e   Jagannath, Sundar ^f   Lonial, Sagar ^g   Orlowski, Robert Z ^h   Sonneveld, Pieter ⁱ   Ludwig, Heinz ^j  

^a HOSPITAL UNIVERSITARIO DE SALAMANCA   (Spain)

^b INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

^c UNIVERSITY OF TURIN   (Italy)

^d ST BARTHOLOMEW S HOSPITAL   (United Kingdom)

^e UNIVERSITY OF BONN   (Germany)

^f ST VINCENT S COMPREHENSIVE CANCER CENTER   (United States)

^g EMORY UNIVERSITY   (United States)

^h CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

ⁱ UNIVERSITY OF NORTH CAROLINA   (United States)

^j ERASMUS MEDICAL CENTER   (Netherlands)

more..

Author keywords

Bortezomib; Multiple myeloma; Practical guidelines; Treatment

Indexed keywords

ACICLOVIR; ALLOPURINOL; AMITRIPTYLINE; ANTIDIARRHEAL AGENT; ANTIEMETIC AGENT; ANTIHYPERTENSIVE AGENT; ATROPINE PLUS DIPHENOXYLATE; BORTEZOMIB; CAPSAICIN; CORTICOSTEROID; CYANOCOBALAMIN; CYTOTOXIC AGENT; DEXAMETHASONE; DOXORUBICIN; ERYTHROPOIETIN; FOLIC ACID; GABAPENTIN; GRANULOCYTE COLONY STIMULATING FACTOR; IRON; LAXATIVE; LOPERAMIDE; MELPHALAN; MINERALOCORTICOID; MITOXANTRONE; PREDNISONE; PROTEASOME INHIBITOR; THALIDOMIDE;

ANEMIA; ASTHENIA; AUTONOMIC NEUROPATHY; BONE MARROW SUPPRESSION; BONE MARROW TRANSPLANTATION; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER REGRESSION; CANCER RELAPSE; CANCER SURVIVAL; CLINICAL TRIAL; CONSTIPATION; CREATININE CLEARANCE; CYTOPENIA; DIARRHEA; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG POTENTIATION; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; FATIGUE; FEBRILE NEUTROPENIA; FEVER; GASTROINTESTINAL SYMPTOM; HEMODIALYSIS; HERPES ZOSTER; HUMAN; HYDRATION; INFECTION PREVENTION; KIDNEY DISEASE; KIDNEY DYSFUNCTION; KIDNEY FAILURE; LETHARGY; LIVER DISEASE; LIVER FAILURE; MALAISE; MULTIPLE MYELOMA; NAUSEA; NEUROTOXICITY; NEUTROPENIA; ORTHOSTATIC HYPOTENSION; PAIN; PARESTHESIA; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SALT INTAKE; STEM CELL; SURVIVAL TIME; THROMBOCYTE TRANSFUSION; THROMBOCYTOPENIA; TREATMENT OUTCOME; TUMOR LYSIS SYNDROME; VITAMIN SUPPLEMENTATION; VOMITING; WEAKNESS;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BORONIC ACIDS; HUMANS; MULTIPLE MYELOMA; PERIPHERAL NERVOUS SYSTEM DISEASES; PROGNOSIS; PYRAZINES; SURVIVAL ANALYSIS; THROMBOCYTOPENIA;

EID: 31444442200     PISSN: 10837159     EISSN: None     Source Type: Journal    
DOI: 10.1634/theoncologist.11-1-51     Document Type: Review

References (32)

1. San Miguel JF, Gutierrez N, Garcia-Sanz R et al. Thalidomide and new drugs for the treatment of multiple myeloma. Hematol J 2003;4(suppl 3):201-207.
2. Bruno B, Rotta M, Giaccone L et al. New drugs for treatment of multiple myeloma. Lancet Oncol 2004;5:430-442.
3. Hideshima T, Mitsiades C, Akiyama M et al. Molecular mechanisms mediating antimyeloma activity of proteasome inhibitor PS-341. Blood 2003;101:1530-1534.
4. Mitsiades N, Mitsiades CS, Richardson PG et al. The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications. Blood 2003;101:2377-2380.
5. Orlowski RZ, Stinchcombe TE, Mitchell BS et al. Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies. J Clin Oncol 2002;20:4420-4427.
6. Richardson PG, Barlogie B, Berenson J et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 2003;348:2609-2617.
7. Bladé J, Samson D, Reece D et al. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haematopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant. Br J Haematol 1998;102:1115-1123.
8. Jagannath S, Barlogie B, Berenson J et al. A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma. Br J Haematol 2004;127:165-172.
9. Richardson P, Barlogie B, Berenson J et al. Survival, duration of response, and time to progression with bortezomib in patients with relapsed and refractory multiple myeloma: an update with additional follow up. Hematol J 2004;5(suppl 2):S103.
10. Richardson P, Sonneveld P, Schuster M et al. Bortezomib demonstrates superior efficacy to high-dose dexamethasone in relapsed multiple myeloma: final report of the APEX study. Blood 2004;104:abstract 336.5. Available at http://www.abstracts2view.com/hem_sandiego2004. Accessed January 9, 2005.
11. Sonneveld P, Richardson PG, Schuster MW et al. Bortezomib is more effective than high-dose dexamethasone at first relapse and provides better outcomes when used early rather than as later salvage therapy in relapsed multiple myeloma. Haematologica 2005;90(suppl 2):159.
12. Richardson PG, Barlogie B, Berenson J et al. Prognostic factors for response parameters and overall survival in patients with multiple myeloma (MM) following treatment with bortezomib. Blood 2003;102:446a.
13. Berenson JR, Jagannath S, Barlogie B et al. The safety of prolonged therapy with the proteasome inhibitor bortezomib (Velcade) in relapsed and/or refractory multiple myeloma (MM). Hematol J 2004;5 (suppl 2):S129.
14. Voorhees PM, Dees EC, O'Neil B et al. The proteasome as a target for cancer therapy. Clin Cancer Res 2003;9:6316-6325.
15. Berenson J, Yang H, Swift R et al. Bortezomib in combination with melphalan in the treatment of relapsed or refractory multiple myeloma: a phase I/II study. Blood 2004;104:64a.
16. Ma MH, Yang HH, Parker K et al. The proteasome inhibitor PS-341 markedly enhances sensitivity of multiple myeloma tumor cells to chemotherapeutic agents. Clin Cancer Res 2003;9:1136-1144.
17. Hideshima T, Richardson P, Chaunhan D et al. The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Res 2001;61:3071-3076.
18. Orlowski RZ, Voorhees PM, Garcia RA et al. Phase I trial of the proteasome inhibitor bortezomib and pegylated liposomal doxorubicin in patients with advanced hematologic malignancies. Blood 2005;105:3058-3065.
19. Alexanian R, Wang LM, Weber DM et al. VTD (Velcade, thalidomide, dexamethasone) as primary therapy for newly diagnosed multiple myeloma. Blood 2004;104:64a.
20. Zangari M, Barlogie B, Hollmig K et al. Marked activity of Velcade plus thalidomide (V+T) in advanced and refractory multiple myeloma (MM). Blood 2004;104:413a.
21. Jagannath S, Barlogie B, Berenson JR et al. Bortezomib in recurrent and/or refractory multiple myeloma. Initial clinical experience in patients with impaired renal function. Cancer 2005;103:1195-1200.
22. Rosinol L, Montoto M, Cibeira MT et al. Bortezomib-induced severe hepatitis in multiple myeloma: a case report. Arch Intern Med 2005;165: 464-465.
23. Millennium Pharmaceuticals, Inc. Velcade™ (bortezomib) for injection. Prescribing information. Cambridge, MA: Millennium Pharmaceuticals, Inc., 2004.
24. Richardson PG, Briemberg H, Jagannath S et al. Characterization and reversibility of peripheral neuropathy in patients with advanced multiple myeloma treated with bortezomib (VELCADE). The SUMMIT and CREST Study Group. Hematol J 2004;5(suppl 2):S129.
25. Calhoun EA, Welshman EE, Chang CH et al. Psychometric evaluation of the Functional Assessment of Cancer Therapy/Gynecologic Oncology Group-Neurotoxicity (Fact/GOG-Ntx) questionnaire for patients receiving systemic chemotherapy. Int J Gynecol Cancer 2003;13: 741-748.
26. Lonial S, Waller EK, Richardson PG et al. Evaluation of the degree of thrombocytopenia and associated risk factors following bortezomib therapy for relapsed multiple myeloma. Blood 2003;102:447a.
27. Fitzgerald M, Fraser C, Webb I et al. Normal hematopoietic stem cell function in mice following treatment with bortezomib. Biol Blood Marrow Transplant 2003;9:121.
28. Lee S, Richardson PG, Barlogie B et al. Quality of life (QOL) and clinical benefit assessment in patients with relapsed and refractory multiple myeloma (MM) treated with bortezomib. Proc Am Soc Clin Oncol 2003;22:582.
29. Mehta J, Jakob C, Singhal S et al. Bortezomib causes tumor lysis syndrome in approximately 1% of patients with myeloma. Blood 2003;102:386b.
30. Terpos E, Politou M, Rahemtulla A. Tumour lysis syndrome in multiple myeloma after bortezomib (VELCADE) administration. J Cancer Res Clin Oncol 2004;130:623-625.
31. Jagannath S, Durie B, Wolf J et al. Bortezomib (Velcade, formerly PS-341) as first-line therapy in patients with multiple myeloma (MM). Blood 2003;102.
32. 12 deficiency in patients with plasma cell dyscrasias: a retrospective review. Cancer 2004;101:790-795.